Results 321 to 330 of about 119,519 (336)

Targeting Upstream Janus Kinases

2016
Janus kinases (JAKs) are the tyrosine kinases that are the principal activators of STAT proteins – particularly downstream of cytokine receptors – during normal development and homeostasis. The JAKs also make a major contribution to the hyperactivation of STATs observed in various malignancies, including through mutation of the JAKs themselves in ...
Parisa Rasighaemi, Alister C. Ward
openaire   +1 more source

Janus Kinase

2021
Bobin George Abraham, Juuli Raivola, Anniina Virtanen, Olli Silvennoinen   +3 more
openaire   +1 more source

Janus kinases inhibitors

Cahiers Santé Médecine Thérapeutique, 2022
El Mehdi Boudhar, M El Mandour, Abdelhafid Elguich, Hajar Sahimi, Hasna Hassikou   +4 more
openaire   +1 more source

Janus Activated Kinase inhibition in Myelofibrosis

Indian Journal of Cancer, 2012
Janus Activated Kinase (JAK) 2 plays an important role in the pathogenesis of myelofibrosis (MF). Ruxolitinib (INCB018424, Jakafi) is a potent dual JAK1 and JAK2 inhibitor. In November 2011, it became approved by the US FDA for the treatment of intermediate or high-risk MF.
openaire   +2 more sources

Thromboembolism and Janus Kinase Inhibitors

Drug Safety, 2020
Fowzia Ibrahim, David L. Scott
openaire   +3 more sources

Janus Kinase

2006
openaire   +2 more sources

Janus Kinases (JAK)

2012
Marissa K. Caldow, David Cameron-Smith
openaire   +1 more source

Janus Kinases

2008
openaire   +1 more source

Janus Kinase (JAK) Inhibitors

2022
Courtney E. Heron, Lindsay C. Strowd, Steven R. Feldman   +2 more
openaire   +1 more source

Janus Kinase

2011
openaire   +1 more source